Poking Holes in Genetic Privacy

“Poking Holes in Genetic Privacy.” By Gina Kolata, The New York Times.

Not so long ago, people who provided DNA in the course of research studies were told that their privacy was assured. Their DNA sequences were on publicly available Web sites, yes, but they did not include names or other obvious identifiers. These were . . . → Read More: Poking Holes in Genetic Privacy

“I Discovered the BRCA1 Gene”

“I Discovered the BRCA1 Gene.” By Sara Reardon, Slate.

Mary-Claire King, the geneticist who discovered the BRCA1 gene, says she is delighted by the U.S. Supreme Court ruling that makes it illegal to patent it. Her work inspired the forthcoming film Decoding Annie Parker, in which she is portrayed by Helen Hunt.

Sara Reardon: . . . → Read More: “I Discovered the BRCA1 Gene”

Supreme Court says natural human genes can't be patented

“Supreme Court says natural human genes can’t be patented.” By Pete Williams and Erin McClam, NBC News.

The Supreme Court ruled unanimously Thursday that natural human genes cannot be patented by companies, but it said that synthetically produced genetic material can — a mixed ruling for the biotechnology industry. A naturally occurring piece of DNA . . . → Read More: Supreme Court says natural human genes can’t be patented

Facebook Is Officially OK With (Some) Mastectomy Photos

“Facebook Is Officially OK With (Some) Mastectomy Photos” By Courtney Subramanian, Time.

After more than 20,000 people signed an online petition asking Facebook to stop censoring photos of people who have undergone mastectomies, the social network has for the first time posted its policy on the images. The company said in a statement that it . . . → Read More: Facebook Is Officially OK With (Some) Mastectomy Photos

Susan Komen CEO's salary draws fire as donations drop, races are canceled

“Susan Komen CEO’s salary draws fire as donations drop, races are canceled” By Lisa Myers and Talesha Reynolds, NBC News.

When the Susan G. Komen Foundation announced last week that it was canceling half of its 3-Day races next year, the charity blamed the economy. But it also acknowledged that its decision to stop providing . . . → Read More: Susan Komen CEO’s salary draws fire as donations drop, races are canceled

Did Backlash Prompt Komen’s Cancellations?

“Did Backlash Prompt Komen’s Cancellations?” By Winston Ross, The Daily Beast.

Lisa Bonchek Adams hopped off the Komen “bandwagon” years ago, long before the charity that puts on “Race For The Cure” events all over the world threatened to yank its funding for Planned Parenthood. Adams was diagnosed with breast cancer in 2006, and in . . . → Read More: Did Backlash Prompt Komen’s Cancellations?

The sad decline of Komen for the Cure

“The sad decline of Komen for the Cure.” By Mary Elizabeth Williams, Salon.

The streets will be a little less pink next year. One of the world’s most prominent breast cancer organizations, Susan G. Komen for the Cure, announced this week it’s canceling its annual “3-Day” fundraising event — a “60-mile walk for women and . . . → Read More: The sad decline of Komen for the Cure

Why is Nancy Brinker still CEO of the Susan G. Komen foundation?

“Why is Nancy Brinker still CEO of the Susan G. Komen foundation?” By Jena McGregor, The Washington Post.

The Susan G. Komen foundation announced Monday that in 2014 the breast cancer charity would be cancelling seven of its three-day walks, or half of its annual multi-day events. The organization said the cancellations were a result . . . → Read More: Why is Nancy Brinker still CEO of the Susan G. Komen foundation?

New drugs trail many old ones in effectiveness against disease

“New drugs trail many old ones in effectiveness against disease.” By Sharon Begley, Reuters.

Despite the more than $50 billion that U.S. pharmaceutical companies have spent every year since the mid-2000s to discover new medications, drugmakers have barely improved on old standbys developed decades ago. In the early years, drugs easily beat the placebo: They . . . → Read More: New drugs trail many old ones in effectiveness against disease

The $2.7 Trillion Medical Bill

“The $2.7 Trillion Medical Bill.” By Elisabeth Rosenthal, The New York Times.

Deirdre Yapalater’s recent colonoscopy at a surgical center near her home here on Long Island went smoothly: she was whisked from pre-op to an operating room where a gastroenterologist, assisted by an anesthesiologist and a nurse, performed the routine cancer screening procedure in . . . → Read More: The $2.7 Trillion Medical Bill

Articles & Posts